September 28, 2023

Intrommune Therapeutics Announces Successful POC Study of Allergy Treatment Option

by admin in Food Allergy News0 Comments

Intrommune Therapeutics has been testing a biopharmaceutical food allergy treatment using oral mucosal immunotherapy (OMIT). The treatment, which adds an element to toothpaste during tooth brushing, has successfully undergone proof-of-concept study.

The study tested a version of OMIT for allergic rhinitis as a pilot to test the concept. Published in the journal Rhinology, the results show that the delivery method for treatment is safe and efficacious when compared to sblingual drops. It also fosters higher adherence to treatment regimens.

Intrommune is testing its INT-301 product for peanut allergies.

The trial and its proof of concept will mean that the company can move forward on testing OMIT for delivery of oral immunotherapy options. Beginning with its peanut allergy product. The lead author of the paper is, Itrommune notes, also a peanut allergy sufferer.

The company plans to create OMIT therapies for a variety of allergies, including the “big 8:” peanut, tree nut, milk, egg, what, fish, and shellfish.

Leave a Reply

Your email address will not be published. Required fields are marked

{"email":"Email address invalid","url":"Website address invalid","required":"Required field missing"}